In this prospective active-controlled randomized trial the investigators will assess for the first time ever the different local treatments of vulvovaginal atrophy in breast cancer patients on endocrine therapy. These patients are currently inadequately treated based on ignorance of possible treatment modalities and stigmatization of vulvovaginal atrophy.

开始日期2022-03-21

申办/合作机构

Ghent University Hospital

[+1]

NCT05246865 / RecruitingN/AIIT

The Role of 11-oxygenated Androgens in Androgen Excess and Metabolic Dysfunction of Women With Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) affects 10% of all women and usually presents with irregular menstrual periods and difficulties conceiving. It is also a lifelong metabolic disorder and affected women have an increased risk of type 2 diabetes, high blood pressure, and heart disease. Increased blood levels of male hormones, also termed androgens, are found in most PCOS patients. Androgen excess appears to impair the ability of the body to respond to the sugar-regulating hormone insulin (also termed 'insulin resistance'). Androgens circulating in the blood in women with PCOS are comprised of classic androgens (for example testosterone), and the less-characterised 11-oxygenated androgen subclass that arises from the adrenal glands. The investigators have recently demonstrated that 11-oxygenated androgens make up the majority of circulating androgens in women with PCOS.
In preliminary studies using minimally invasive adipose tissue sampling, the investigators have found that the fat tissue of women with PCOS overproduces classic androgens. This can lead directly to disturbances in the ability of fat cells to store fat effectively (lipotoxicity), resulting in insulin resistance and the consequent risk of liver damage. However, there are no published studies on in vivo androgen concentrations in the adipose tissue of women with PCOS. Furthermore, the scientific community do not have any information on whether adipose concentrations of 11-oxygenated androgens are also increased in women with PCOS.
Research Questions The investigators aim to examine the metabolism of classic and 11-oxygenated androgens in detail in both circulations and in the adipose tissue of women with PCOS. The investigators will examine how precursor variants of both 11-oxygenated and classic androgens, which are converted by the body into active hormones, are broken down (metabolised) within the adipose tissue of women with PCOS. The investigators will also investigate if the 11-oxygenated androgens have a differential impact on metabolic function as compared to classic androgens. This will give important insights into the adipose tissue metabolome in women with PCOS, and how locally generated androgens impact on adipose tissue function and metabolic risk.

开始日期2021-10-10

申办/合作机构

University of Birmingham

100 项与脱氢表雄酮相关的临床结果

登录后查看更多信息

100 项与脱氢表雄酮相关的转化医学

登录后查看更多信息

100 项与脱氢表雄酮相关的专利（医药）

登录后查看更多信息

8,652

项与脱氢表雄酮相关的文献（医药）

2024-12-31·GYNECOLOGICAL ENDOCRINOLOGY

Protective effect of Yunkang oral liquid via regulating androgen receptor in polycystic ovary syndrome rats

Article

作者: Xu, Wanfeng ; Chen, Suhong ; Zheng, Xiang ; Li, Bo ; Zhou, Chuanjie ; Lv, Guiyuan ; Jia, Jiujie

Objectives: This study aimed to explore the effect and mechanism of Yunkang oral liquid (YK) on polycystic ovary syndrome (PCOS). Methods: PCOS model rats were prepared by injecting exogenous androgen dehydroepiandrosterone, and YK was administered simultaneously for 28 days during modeling. The morphology of ovaries and uterus was observed using H&E staining, and serum levels of testosterone (T), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were determined by radioimmunoassay. Additionally, serum lipids (TG, HDL-c), blood glucose (GLU), and aminotransferase (AST, ALT) levels were detected. The expression of androgen receptor (AR) protein was determined by Western blotting. Results: YK treatment resulted in reduced serum levels of T, LH and FSH, ameliorated ovarian polycystic-like pathological changes and uterine morphology in PCOS rats, and decreased serum TG, GLU, AST and ALT levels, elevated serum HDL-c levels, and improved abnormalities of glycolipid metabolism accompanying PCOS. Moreover, YK decreased the expression of ovarian AR in PCOS rats. Conclusions: This study indicates that YK may protect the ovaries by inhibiting the expression of AR, which could be a potential treatment for PCOS.

2024-12-31·Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Comparative effects of the antioxidant glutathione with metformin and Diane-35 on hormonal, metabolic, and inflammatory indicators in a DHEA-induced PCOS rat model

Article

作者: Tanoglu, Fatma Basak ; Tok, Olgu Enis ; Timur, Hikmet Tunç ; Özkara, Gülçin ; Coşar, Aslı ; Çetin, Çağlar ; Neccar, Duygu ; Özcan, Pınar

OBJECTIVE:

Comparison of hormonal, metabolic and inflammatory markers of glutathione with metformin and Diane-35 in a rat model of PCOS induced by dehydroepiandrosterone.

METHODS:

Twenty-five female rats were randomized into four groups. Group 1 was administered a subcutaneous dose of 0.2 ml saline/day. Group 2 was given 0.2 ml of 1% carboxymethyl cellulose (CMC)/day orally for 28 days. A PCOS model was established with DHEA in rats. Group 3 was given 4.5 mg/kg/day of Diane-35 orally dissolved in 1% CMC for 28 days. Group 4 was given 300 mg/kg/day of metformin orally dissolved in 1 ml of saline for 28 days, and Group 5 was administered 100 mg/kg of glutathione intraperitoneally on days 35, 42, and 49. On day 56, the rats were sacrificed. Serum markers and follicle count were examined.

RESULTS:

Serum IL-6, hs-CRP, insulin, testosterone, SHBG, and MDA values were significantly lower in the glutathione group than in the PCOS group (p = 0.0006, p = 0.023, p = 0.0082, p = 0.0007, p = 0.0048, and p < 0.0001, respectively).The number of all follicles was similar between the control and glutathione groups (p < 0.05). When we compared the other groups with the PCOS group, the number of primary, secondary, atretic, and cystic follicles was significantly lower in the metformin and glutathione groups. The number of primordial and antral follicles was significantly higher than in the PCOS group.

CONCLUSIONS:

Glutathione plays anti-inflammatory and antioxidant roles, similar to metformin, by lowering serum IL-6, insulin, testosterone, CRP, and MDA levels; decreasing atretic/cystic follicle count; and improving antral follicle count and folliculogenesis in PCOS patients.

2024-12-31·STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS

Examination-related anticipatory levels of dehydroepiandrosterone and cortisol predict positive affect, examination marks and support-seeking in college students

Article

作者: Mendez-Lopez, Magdalena ; Hidalgo, Vanesa ; Fidalgo, Camino ; Garces-Arilla, Sara ; Salvador, Alicia

Dehydroepiandrosterone (DHEA) and cortisol release appear to have contrasting effects on stress perception during stressful tasks. This study aimed to investigate anticipatory examination stress in college students by considering DHEA, cortisol, psycho-emotional aspects and examination performance. Seventy-six students (66 females, 10 males; age range 18-25 years) provided saliva samples and completed questionnaires in two sessions 48 hours apart. During the second session, the students performed the examination. The questionnaires used were the State-Trait Anxiety Inventory, the Positive and Negative Affect Scale, and the Brief-Coping Orientation to Problems Experienced Inventory. DHEA, cortisol, anxiety and negative affect showed an anticipatory rise before the examination (all ps < 0.001). This rise of DHEA and cortisol was associated with lower positive affect (p = 0.001 and p = 0.043, respectively). However, only the DHEA anticipatory levels were linked to poorer examination marks (p = 0.020). Higher levels of the DHEA/cortisol ratio in anticipation of the examination were related to lower scores on the support-seeking strategy (p = 0.022). There was no association between DHEA and cortisol levels and anxiety, negative affect, active and avoidant coping strategies, or academic record. These results suggest that how DHEA and cortisol respond in anticipation of examination stress significantly impacts students' emotional well-being during examination periods and how they cope with stress. They also suggest that levels of DHEA in anticipation of an academic stressor have detrimental effects on stress management.

项与脱氢表雄酮相关的新闻（医药）

2024-09-10

·drugs

Review Weighs Treatments for Genitourinary Symptoms of Menopause

TUESDAY, Sept. 10, 2024 -- Vaginal estrogen, vaginal dehydroepiandrosterone (DHEA), oral ospemifene, and vaginal moisturizers may be beneficial for some genitourinary symptoms of menopause (GSM), according to a review published online Sept. 10 in the Annals of Internal Medicine . Elisheva R. Danan, M.D., M.P.H., from the University of Minnesota in Minneapolis, and colleagues examined the effectiveness and harms of vaginal estrogen, nonestrogen hormone therapies, and vaginal moisturizers for treatment of GSM in a systematic review of randomized controlled trials (RCTs). A total of 46 RCTs assessing vaginal estrogen, nonestrogen hormones, vaginal moisturizers, or multiple interventions were identified from 11,993 citations. The researchers found that vaginal estrogen may improve vulvovaginal dryness, dyspareunia , the most bothersome symptom, and treatment satisfaction compared with placebo or no treatment. Vaginal DHEA may improve dryness, dyspareunia, and distress, bother, or interference from genitourinary symptoms compared with placebo; oral ospemifene may improve dryness, dyspareunia, and treatment satisfaction; and dryness may also be improved by vaginal moisturizers (all low certainty of evidence [COE]). No benefit or uncertain effects (low and very low COE, respectively) may be provided by vaginal testosterone, systemic DHEA, vaginal oxytocin, and oral raloxifene or bazedoxifene. Reporting was limited by studies of short duration that were insufficiently powered to assess infrequent serious harms. "Future studies would be strengthened by standard definitions of symptoms and uniform diagnostic criteria for GSM, a common set of validated outcome measures and reporting standards, and attention to clinically relevant patient populations and intervention comparisons," the authors write.

临床结果

2024-07-19

·Outsourcing Pharma

Avista and Hamilton Lane Join Forces to Propel Growth and Innovation at Cosette Pharmaceuticals

The companies will jointly control Cosette, with a focus on accelerating innovation and growth. Since Avista's initial investment in Cosette in December 2018, Cosette has launched new products through research and development efforts, acquisitions, and licensing deals. This includes the acquisition of Ambien and Ambien CR in the United States from Sanofi US. The company reports that these initiatives have led to significant EBITDA growth and free cash flow generation, positioning Cosette for future opportunities. Apurva Saraf, president and CEO of Cosette, said: “This partnership is a testament to the remarkable transformation our business has achieved over the past four years, driven by an unwavering commitment to strategic business development and operational excellence. I am immensely proud of the entire Cosette team for their dedication in delivering this robust growth. “We have successfully diversified our portfolio with branded products such as Clomid, Ambien, and Benicar, along with innovative, patent-protected drugs like Vyleesi and Intrarosa. With our strong R&D and business development pipeline, we are well positioned to drive substantial growth in partnership with Avista and Hamilton Lane." Financial strength and future opportunities for Cosette Pharmaceuticals The companies indicate that this transaction will enhance Cosette's balance sheet and support growth through investments in R&D and strategic acquisitions. The goal is to build a durable, high-growth, branded pharmaceutical company. As part of the transaction, Cosette has also secured a new term loan financing with Hayfin Capital Management and a new revolving credit facility provided by UBS Investment Bank, Capital One, National Association, and Santander Corporate & Investment Bank, who acted as joint lead arrangers and joint bookrunners for the financing. googletag.cmd.push(function () { googletag.display('text-ad1'); }); David Burgstahler, managing partner and CEO of Avista, added: “We value Avista's long-term relationship with Hamilton Lane and look forward to collaborating with them as a strategic partner to drive growth and value at Cosette. Our collective expertise will prove invaluable as Cosette evaluates larger M&A opportunities as part of the company's growth strategy.” Cosette Pharmaceuticals has made significant contributions to the pharmaceutical industry, particularly in the realm of specialty pharmaceuticals. The company has a strong focus on developing and commercializing branded and generic products that address unmet medical needs. With a diverse portfolio that includes notable products, Cosette has demonstrated a commitment to innovation and patient care. It says its strategic approach to research and development, coupled with targeted acquisitions and licensing deals, has enabled them to introduce groundbreaking therapies and expand their market presence, positively impacting patient outcomes and advancing healthcare solutions.

并购引进/卖出

2024-07-04

·药时代

青蒿素新功效，有望治疗这种常见病

2015年，屠呦呦团队因从中药中分离出青蒿素并将其应用于疟疾治疗，摘取了诺贝尔生理学或医学奖。 2021年，世界卫生组织宣布中国通过消除疟疾认证，中国成为世卫组织西太平洋区域三十多年来第一个获得无疟疾认证的国家。被誉为“中国神草”的青蒿素，每年都在挽救全球无数疟疾患者。转眼三年之后，复旦大学团队在Science杂志发论文，揭示了青蒿素在治疗多囊卵巢综合征方面的潜力。 2024年6月13日，复旦大学基础医学院团队联合复旦大学附属中山医院团队，合作在《科学》（Science）杂志上在线发表了关于青蒿素研究的最新成果——《青蒿素类衍生物可通过增强LONP1-CYP11A1互作治疗多囊卵巢综合征》（Artemisinins ameliorate polycystic ovarian syndrome by mediating LONP1-CYP11A1 interaction），研究团队发现青蒿素类衍生物能够显著改善多囊卵巢综合征的疾病表型。论文发表页面丨图源Science 站在巨人的肩膀上多囊卵巢综合征（polycystic ovary syndrome，PCOS）是最常见的生殖内分泌紊乱疾病之一，也是育龄期女性不孕的罪魁祸首，全球发病率约为10%-13%。根据2003年鹿特丹发布的诊断标准，满足以下三种特征的其中两项，即可确诊为PCOS：一是不排卵或偶发性排卵，即无月经或月经周期紊乱；二是高雄激素血症或高雄激素的临床表现；三是卵巢呈现多囊样改变。其中雄激素升高是最典型的症状之一，也是导致患者卵泡发育受损、排卵异常的直接诱因，降低PCOS患者的雄激素水平是目前治疗PCOS的主要方式。此外，PCOS患者往往伴有肥胖、胰岛素抵抗及糖尿病代谢异常，随着疾病的发展，还会引起心脑血管疾病、生殖系统肿瘤以及精神性障碍等疾病，对女性生殖生育和生命健康带来了严重威胁。然而，学界尚未理清PCOS发病诱导机制，临床上只能对症下药，多使用联合口服避孕药以降低高雄激素血症，但并不能改善不孕症以及多囊卵巢的形态。总而言之，治疗效果并不理想。青蒿素是来源于黄花蒿的倍半萜内酯化合物，由于其疗效稳定且副作用小，临床上一直将其作为一线抗疟疾药物使用。疟疾是一种经按蚊叮咬而感染疟原虫所引起的虫媒传染病，而PCOS是诱因机制尚不明确的生殖内分泌紊乱疾病，乍一看，疟疾和PCOS两者是八竿子打不着的关系，研究人员是如何发挥奇思妙想，将青蒿素与PCOS联系在一起的呢？ “这主要得益于站在巨人的肩膀上。”该项研究的第一作者复旦大学基础医学院副教授刘洋告诉《返朴》。大概从2016年开始萌生了启动这项研究的想法，彼时他正在复旦大学读博后，挂靠在复旦大学附属妇产科医院，研究脂肪细胞的发育及代谢调控相关方向。在个人研究领域与临床常见女性生殖疾病之间找到结合点进而解决临床问题，是刘洋的初心所在。刘洋的博士生导师——汤其群教授，一直深耕于脂肪细胞的研究。学界将脂肪组织分为三种类型，白色脂肪负责储存能量，棕色和米色脂肪可以将营养物质代谢产生的能量转化成热能，用于维持体温。人体内经典的棕色脂肪只出现在婴幼儿时期，而米色脂肪主要分布于成年人体内，棕色脂肪的激活和白色脂肪的米色化，可以促进机体能量消耗，一直被视为抵抗肥胖的有效策略。由此，如何激活白色脂肪的米色化进而改善代谢，成为领域内的前沿问题。 2015年，屠呦呦教授获得诺贝尔生理学或医学奖，青蒿素一时间成为学界研究的香饽饽。2016年，汤其群教授团队在Cell Research发表论文，通过系统筛选了促进白色脂肪米色化的小分子化合物，发现青蒿素类衍生物——青蒿素甲醚（ATM）能够促进白色脂肪米色化，同时增强棕色脂肪的功能，对肥胖诱导的代谢综合征发挥了很好的预防和治疗作用。同年，PNAS期刊上发表了棕色脂肪移植能够治疗多囊卵巢综合征的重要工作，发现通过在PCOS模型大鼠体内移植外源性棕色脂肪组织（BAT）之后，内源性BAT被显著激活，胰岛素抵抗明显改善，规律性排卵恢复，受孕率提高。需要补充说明的是，此前已有研究表明PCOS患者体内棕色脂肪功能异常，进而出现胰岛素抵抗等代谢紊乱症状。换句话说，棕色脂肪组织对PCOS治疗举足轻重。这两篇文章给研究团队指引了一个方向，青蒿素是否能够影响PCOS的发生发展呢？抽丝剥茧，乘胜追击青蒿素类衍生物抑制PCOS发生的分子机制丨图源：论文为了研究青蒿素对PCOS是否有治疗作用，研究团队采用了外源雄激素——脱氢表雄酮（DHEA）构建了PCOS样小鼠及大鼠模型，同时团队也采用了胰岛素和人绒毛膜促性腺激素hCG构建了另一种PCOS样大鼠模型，并使用青蒿素类衍生物蒿甲醚（ATM）处理上述模型。实验结果让研究团队非常兴奋，无论是腹腔注射还是口服，ATM都能够显著抑制血清雄激素水平，改善PCOS样动物模型的发情周期，降低卵巢中囊状卵泡的数量，并且能够提高PCOS样大鼠的生育能力。那么，蒿甲醚是通过何种机制降低雄激素水平的呢？团队带着这些问题进一步研究。下丘脑-垂体-卵巢轴在类固醇激素生成中发挥着重要的神经内分泌作用，卵泡刺激素（FSH）和黄体生成素（LH）是控制类固醇激素合成的上游激素。以此为切入点，研究团队探究了ATM是否直接参与控制雄激素合成的上游激素。然而在PCOS样模型中，无论是腹腔给药还是口服给药，ATM对FSH和LH均无影响，这表明ATM不是通过改变促性腺激素的生成进而调控雄激素。团队进一步假设ATM可能直接通过靶向卵巢来调节睾酮水平。为了验证这一想法，研究团队测定了卵巢卵泡膜间质细胞上清液中的类固醇激素。实验表明，青蒿素类衍生物抑制了卵巢卵泡膜间质细胞的类固醇生成过程和随后的雄激素合成。为了进一步探究青蒿素衍生物诱导雄激素合成减少的细胞途径，团队对ATM处理前后分离得到的卵泡膜间质细胞进行了基于质谱的相对定量蛋白质组学分析，发现CYP11A1是ATM诱导下调最显著的蛋白。CYP11A1能够催化胆固醇转化为孕烯醇酮，是雄性激素合成的限速酶。为了验证蛋白质组学数据，研究团队检测了小鼠和大鼠卵泡膜间质细胞中类固醇激素合成酶的表达，结果发现青蒿素类衍生物能够剂量依赖性地下调CYP11A1蛋白。而在CYP11A1缺失的细胞中，青蒿素类衍生物无法进一步抑制雄激素合成，表明其通过下调CYP11A1蛋白进而抑制雄激素合成。青蒿素衍生物对CYP11A1的调控机制又是如何呢？研究团队使用了免疫共沉淀结合质谱技术（IP-MS）鉴定了ATM处理下CYP11A1的相互作用蛋白，基于IP-MS数据发现了青蒿素类衍生物能够促进LONP1与CYP11A1蛋白相互作用。LONP1是AAA+的线粒体蛋白酶，通过利用ATP水解来降解错误折叠或氧化的蛋白质，在线粒体中蛋白质质量控制中至关重要。研究团队发现LONP1能够响应青蒿素类衍生物进而降解CYP11A1，从而抑制卵巢雄激素的合成。推广大规模临床实验在啮齿类动物上的实验揭示了青蒿素衍生物具有治疗PCOS症状的功效，随后研究团队招募了19名PCOS患者，开展临床研究。参与受试的患者口服双氢青蒿素（40mg,每日3次）持续治疗12周。实验前，所有患者在均有高雄激素血症、月经稀发或闭经、多囊卵巢表现。实验后，所有参与者均未观察到任何副作用。双氢青蒿素治疗显著降低了PCOS患者的血清睾酮水平。抗苗勒氏管激素（anti-Müllerianhormone，AMH）主要由卵巢中窦前卵泡和小窦卵泡的颗粒细胞产生，PCOS患者AMH通常较高，而双氢青蒿素处理显著降低了血清AMH。此外，12名PCOS患者在治疗后恢复了规律的月经周期。总之，双氢青蒿素有效地改善了高雄激素血症，改善了多囊卵巢形态，并有助于PCOS患者月经的正常化。 Science同期发表了瑞典卡罗林斯卡学院Elisabet Stener-Victorin教授题为“Remedy hope for polycystic ovary syndrome”的专评，认为该研究为PCOS治疗提供了新的希望。 “虽然使用外源雄激素造模是业内惯用的操作办法，但这些模型都不能完全复制女性PCOS的复杂情况。本研究使用了围青春期DHEA模型，可以使PCOS样小鼠表现出血清睾酮水平升高，发情周期不规律和多囊卵巢形态。然而，该模型也表现出包括高泌乳素血症在内的其他内分泌疾病，因此它不能完全反映女性PCOS的特征。”尽管团队顶刊上岸，刘洋心中对研究的局限仍然“耿耿于怀”，发展更好地反映人体PCOS发病的动物模型也是领域内亟待解决的问题。 “团队目前正在进一步优化双氢青蒿素的使用剂量和用药时间，后续计划开展更大规模的临床研究。”刘洋表示，“在改善PCOS女性临床症状的基础上，团队未来也将进一步关注PCOS患者的生育能力，以期为育龄期女性解决生育难题提供解决办法。” 参考文献 [1] https://www.eurekalert.org/news-releases/1047601 [2] https://www.science.org/doi/10.1126/science.adk5382 [3] https://www.science.org/doi/10.1126/science.adq0328 封面图来源：123rf 版权声明/免责声明本文为授权转载文章。本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。如有任何问题，请与我们联系。衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 吉利德：Trodelvy的一线生机诺华浙江海盐生产基地启建！扩增放射配体疗法产能阻止司美格鲁肽停药反弹？GLP-1基因疗法来袭点击这里，发现价值信息！

临床研究

100 项与脱氢表雄酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08409	脱氢表雄酮	G03XX01 A14AA07	DB01708

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
潮热	加拿大	Endoceutics, Inc.	2019-11-06
骨质疏松症	加拿大	Endoceutics, Inc.	2019-11-06
性交困难	美国	Millicent Oy	2016-11-16
外阴和阴道萎缩	美国	Millicent Oy	2016-11-16

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乳腺癌	临床3期	-	Endoceutics, Inc.	2018-11-06
乳腺癌	临床3期	-	AMAG Pharmaceuticals, Inc.	2018-11-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03491007 (CTgov)	临床2期	创伤后应激障碍	5	PBO (Placebo)	蓋餘廠築製襯繭鬱鑰觸(繭願襯艱鹹膚鹽壓鑰構) = 鹹獵餘遞鑰積鬱鏇範網廠顧淵餘鏇廠齋鑰鏇夢 (顧網繭窪窪鬱顧鑰構窪, 淵鑰鹽獵鹹範積蓋願製 ~ 膚製艱顧獵網選鏇廠鹹) 更多	-	2023-05-06
				DHEA (DHEA)	夢壓鬱簾夢顧餘鏇鏇範(範願鑰鑰構顧繭製簾願) = 膚蓋鏇遞淵衊鏇壓齋獵鹹築膚憲鹹鏇築積醖襯 (襯齋積憲鏇蓋構鹽艱艱, 範窪淵窪構獵構簾繭蓋 ~ 膚蓋積淵膚鹹糧顧餘製) 更多
NCT01256671 (CTgov)	临床3期	外阴和阴道萎缩	530	DHEA (prasterone)	壓顧齋醖鹽製構襯觸簾(觸範遞鑰憲艱壓選糧襯) = 鹹鹹構範鏇齋窪鹹襯廠鹹夢範願範鹹齋積鬱鑰 (觸壓鑰壓齋糧淵築淵襯, 築鹹艱繭構製築願餘選 ~ 網簾鏇窪製積遞構憲鹹) 更多	-	2017-10-18
NCT01376349 (CTgov)	临床3期	阴道排出物 \| 女性生殖器官肿瘤 \| 乳腺癌	464	prasterone (Arm I Low Dose DHEA)	構憲築鬱鹽憲餘鑰繭鏇(鹽願願窪觸積淵選觸繭) = 構壓積憲繭鹹壓餘蓋艱蓋窪鏇齋構願繭製齋製 (淵構鹽膚製蓋觸鬱醖艱, 壓構廠餘觸遞觸鑰鹽衊 ~ 夢築餘願餘淵獵網鹽選)	-	2017-08-25
				prasterone (Arm II High Dose DHEA)	構憲築鬱鹽憲餘鑰繭鏇(鹽願願窪觸積淵選觸繭) = 憲憲鏇襯壓齋鬱觸鬱願蓋窪鏇齋構願繭製齋製 (淵構鹽膚製蓋觸鬱醖艱, 顧糧遞鑰憲繭遞觸築積 ~ 獵襯構糧網鹽壓觸製積)
NCT01358760 (CTgov)	临床3期	外阴和阴道萎缩	450	Placebo (Placebo)	鑰獵糧餘壓選窪淵鹽範(憲顧窪膚壓壓艱觸艱築) = 蓋鏇糧觸構選鹽繭齋蓋範簾築觸憲築獵鹹鑰積 (膚鏇顧鹽築獵窪遞廠鏇, 築願齋醖觸繭廠窪製顧 ~ 窪網憲夢憲顧鬱鑰廠鹹) 更多	-	2017-06-12
				DHEA (0.25% DHEA)	鑰獵糧餘壓選窪淵鹽範(憲顧窪膚壓壓艱觸艱築) = 糧襯憲齋繭壓鑰憲餘鹹範簾築觸憲築獵鹹鑰積 (膚鏇顧鹽築獵窪遞廠鏇, 鹹鏇鬱簾願範廠蓋糧觸 ~ 遞鏇鬱鹽夢範糧鹹製願) 更多
NCT01846442 (CTgov)	临床3期	外阴和阴道萎缩	218	Placebo (Placebo)	襯蓋鑰餘鏇構餘積衊選(簾鑰願醖淵鑰餘齋選淵) = 夢醖觸憲選範範夢夢醖簾築齋齋遞網鬱襯醖獵 (襯衊顧淵製鏇鏇獵鏇繭, 繭遞鑰壓齋糧淵網鏇艱 ~ 蓋願鏇簾製淵廠築鬱淵) 更多	-	2017-04-28
				DHEA (0.25%) (0.25% DHEA)	襯蓋鑰餘鏇構餘積衊選(簾鑰願醖淵鑰餘齋選淵) = 築獵遞醖鑰窪簾網艱餘簾築齋齋遞網鬱襯醖獵 (襯衊顧淵製鏇鏇獵鏇繭, 鑰蓋憲糧鏇壓糧構醖夢 ~ 憲鑰艱觸鬱憲淵築積顧) 更多
NCT01256684 (CTgov)	临床3期	外阴和阴道萎缩	255	Placebo (Placebo)	選壓鹽衊鹽範襯願衊餘(壓齋鑰糧鑰顧艱齋廠廠) = 窪願鏇顧齋積壓襯夢蓋範鬱醖廠壓醖夢鑰顧獵 (鑰襯壓鹹醖憲構簾製膚, 襯淵憲壓醖築遞衊願夢 ~ 餘鏇鏇顧鑰醖鏇膚觸糧) 更多	-	2017-04-25
				DHEA (0.25% DHEA)	選壓鹽衊鹽範襯願衊餘(壓齋鑰糧鑰顧艱齋廠廠) = 窪壓膚醖齋鏇鹽襯鑰艱範鬱醖廠壓醖夢鑰顧獵 (鑰襯壓鹹醖憲構簾製膚, 網繭廠廠壓獵簾蓋顧齋 ~ 鑰遞範繭選製鑰衊醖夢) 更多
NCT01256671 (Pubmed \| Maturitas) 人工标引	临床3期	外阴和阴道萎缩	521	Prasterone	築鬱蓋廠憲遞壓範鹹鑰(糧襯廠襯鏇壓鬱襯膚淵) = similar improvement results on vaginal dryness and irritation/itching. Highly significant beneficial effects (p<0.0001 versus baseline for all) at gynecological examination on vaginal secretions, color, epithelial integrity and epithelial surface thickness 簾餘願膚衊膚艱膚襯製 (鹹遞廠構鬱醖選鏇壓淵 ) 更多	积极	2015-05-01
NCT02150330 (Pubmed \| Taiwan J Obstet Gynecol)	临床3期	卵巢疾病	10	DHEA supplementation	壓壓鏇糧襯淵衊夢顧齋(壓獵窪鬱觸膚網獵網艱) = 鏇衊襯獵網醖遞鬱膚觸膚顧襯築繭簾鹽範糧鹹 (獵築夢構鏇餘鹽衊夢範 )	-	2015-04-01
NCT01358760 (Pubmed \| Climacteric) 人工标引	临床3期	外阴和阴道萎缩	-	dehydroepiandrosterone	襯憲窪醖壓壓築艱廠築(窪築蓋壓繭壓壓鏇網遞) = In parallel, the statistical significance over placebo (p value) on MBS vaginal dryness at 6 weeks was 0.09 followed by an increase to 0.198 at 12 weeks. 願製窪遞艱餘鏇糧醖夢 (醖願窪觸積構齋壓製獵 ) 更多	不佳	2015-01-01
				Placebo
NCT02432248 (Pubmed \| J Biol Chem)	N/A	对促排卵反应不佳辅助	386	DHEA treatment	製醖遞窪願糧築願鬱衊(鬱齋遞鏇積範餘鑰觸鹽) = 積壓齋膚鏇淵繭壓鹽範積簾觸觸選鬱鏇構繭觸 (選選選淵獵選艱鹽觸艱 ) 更多	积极	2014-01-01
				dehydroepiandrosterone (Control group)	製醖遞窪願糧築願鬱衊(鬱齋遞鏇積範餘鑰觸鹽) = 願醖積願構餘襯觸壓獵積簾觸觸選鬱鏇構繭觸 (選選選淵獵選艱鹽觸艱 ) 更多